Glomerulonephritis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Glomerulonephritis Treatment Market is Segmented By Disease Type (Acute, Chronic), By Drug Class (Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs), Diuretics, Calcium Channel Blockers, Beta-Blockers, Alpha-Blockers, Alkylating Agents, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Glomerulonephritis Treatment Market Overview

Glomerulonephritis Treatment Market is expected to reach at a CAGR 5.4 % during the forecast period (2024-2031).

Glomerulonephritis, also known as Bright's disease, is a progressive kidney disease that damages the glomeruli—the filtering units of the kidney that create urine as waste.

Glomerulonephritis Treatment Market Scope

To Know More Download Sample

Glomerulonephritis Treatment Market Dynamics

The increasing number of clinical trials for drug development by the market players is expected to drive market growth.

MorphoSys AG is a biopharmaceutical company headquartered near Munich, Germany and has a wholly-owned subsidiary, MorphoSys US Inc. The company has more than 100 drugs in its wider pipeline that are being investigated for various diseases. In contrast, many of these are being developed in partnership with pharma and biotech companies. For instance, Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys’ HuCAL antibody library and directed against CD38. It is currently under investigation in phase Ib/IIa. The safety and efficacy of Felzartamab are currently evaluated in patients with glomerulonephritis, including anti-PLA2R antibody-positive membranous nephropathy (MN) and IgA nephropathy (IgAN), both autoimmune renal diseases. Moreover, recent advancements in our understanding of the nature and functional abnormalities of acute glomerulonephritis have contributed to the creation of rational and effective therapies. Thus, the market is expected to drive in the forecast period from the above statements.

High cost, less awareness among the population regarding the treatment for glomerulonephritis and fewer side effects of the drugs are some of the factors the market is expected to get hampered in the forecast period.

Glomerulonephritis Treatment Market Industry Analysis

COVID-19 Impact Analysis

The epidemic caused by the SARS-CoV-2 virus resulted in a global lockdown and wreaked havoc on the glomerulonephritis treatment market. Patients with glomerular disease on immunosuppressive drugs may be more susceptible to infections (COVID-19 or other infections). In some patients with glomerular illness, the doctors change their immunosuppressive medication based on their risk of developing end-stage kidney disease and the local transmission of COVID-19. Moreover, Glomerular lesions were reported in a minority of patients with COVID-19, collapsing focal segmental glomerulosclerosis (FSGS), also called COVID-associated nephropathy (COVAN), being the most common. Such patients present with nephrotic-range proteinuria and acute kidney injury (AKI). Similar to HIV-associated nephropathy, COVAN occurred exclusively in Black individuals, and a high proportion tested possessed high-risk APOL1 genotypes.

Additionally, nephrologists and their patients faced difficult decisions regarding the management of glomerular diseases, and the pandemic is interrupting the medical supply chain. Many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the forecast period.

Glomerulonephritis Treatment Market Segment Analysis

Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs) segment is expected to hold the largest market share in glomerulonephritis treatment market

The angiotensin-converting enzyme (ACE) inhibitors (ACEIs) segment is expected to dominate in 2020. ACEIs are renoprotective agents. They decrease intraglomerular pressure and, consequently, glomerular protein filtration by decreasing efferent arteriolar constriction. For instance, Captopril reduces aldosterone secretion by preventing the conversion of angiotensin I to angiotensin II, a powerful vasoconstrictor. Orally, it is quickly absorbed, although its bioavailability is greatly lowered when consumed with meals. Captopril has a one-hour peak concentration and a short half-life. The kidneys eliminate it; however, the dosage is reduced if the patient has a poor renal function. Therefore, it increases the demand for ACEIs drugs to treat glomerulonephritis, due to which the market segment is expected to hold the largest market share in the forecast period.

Glomerulonephritis Treatment Market Geographical Share

North America region holds the largest market share in the global glomerulonephritis treatment market

In 2020, North America accounted for the highest revenue share. The increasing geriatric population, increasing prevalence of chronic kidney diseases, increasing clinical trials by the key players and highly structured health care industry is some of the factors the market is expected to boost in the forecast period. For instance, according to the Centers for Disease Control and Prevention, in 2021, more than 1 in 7, that is, 15% of US adults or 37 million people, are estimated to have CKD. As many as 9 in 10 adults with CKD do not know they have CKD, and about 2 in 5 adults with severe CKD do not know they have CKD. Moreover, Visterra is a clinical-stage biotechnology company committed to developing innovative antibody-based therapies to treat kidney and other hard-to-treat diseases. For instance, the company is developing drugs for C3 Glomerulonephritis, which is in the preclinical stage. Therefore, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Glomerulonephritis Treatment Market Companies

Major key players in the glomerulonephritis treatment market are Visterra, Merck, Camber Pharmaceuticals, Inc., Pfizer Inc., Upsher-Smith Laboratories, LLC, Viatris Inc., Sandoz Inc, Abbott Laboratories, Allergan USA, Inc. and Teva Pharmaceuticals USA, Inc.              

Pfizer Inc:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

­Product Portfolio:

Bumetanide Injection: Bumetanide injection is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion.